John Reed and Naimish Patel

Sanofi R&D team ac­cel­er­ates block­buster de­vel­op­ment ef­forts — while cast­ing doubt on a heavy­weight ri­val’s plans

When Paul Hud­son took the CEO job at Sanofi, it was clear he had one hot hand to play with Dupix­ent and a lega­cy pipeline that was both dis­tract­ed by in­cre­men­tal di­a­betes work and lack­ing much by way of ex­cit­ing new drug pro­grams with block­buster po­ten­tial.

Some, but not much.

So he did what any good CEO would do, jump­ing in af­ter a fal­low stretch: stripped out the un­ap­peal­ing and start­ed hunt­ing new deals, all while nur­tur­ing the cash cow by adding a slate of new de­vel­op­ment pro­grams to build that pipeline-in-a-prod­uct all the Big Phar­mas love.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.